Sandoz Targeted Over Generic Cancer Drug Fusilev

Law360, New York (January 23, 2012, 6:32 PM EST) -- Pharmaceutical company Sandoz Inc. was hit Friday with a patent infringement suit in Nevada federal court by oncology drug specialist Spectrum Pharmaceuticals Inc. and the University of Strathclyde, a Scottish institution, over plans to make a generic version of cancer drug Fusilev.

The suit was prompted by Sandoz’s abbreviated new drug application filed with the U.S. Food and Drug Administration to manufacture 175- and 250-milligram dosage strength versions of levoleucovorin, the generic version of Fusilev.

According to the complaint, Sandoz notified the plaintiffs in December about...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.